Alnylam Pharmaceuticals Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Alnylam Pharmaceuticals Inc.
Private Company Edition: Several drug developers targeting neurological diseases raised venture capital recently. In addition to Nura Bio, Encoded Therapeutics revealed a $135m series D round. Also, Longwood closed a $170m fund and Flagship launched Omega Therapeutics with $85m.
Medtech industry group AdvaMed has developed a registry to share data on how many COVID-19 diagnostic tests are available and where they are, with a goal of foreseeing and nipping in the bud potential test shortages. Thirteen diagnostic manufacturers – including Abbott, Roche, Siemens and Thermo Fisher Scientific – have partnered with AdvaMed on the initiative.
UK patients diagnosed with primary hyperoxaluria Type 1 can now be prescribed lumasiran, which is still being reviewed for EU-wide approval. Patients in the US, Germany and other EU countries can also get the drug under early access schemes.
Poseida, Nkarta and Inventiva raised $224m, $252m and $107.7m, respectively. Also, Forbion raised €185m ($208m) of a new €250m fund and Blackstone closed the last $1.2bn of its $4.6bn fund for public and private company deals, and Ascendis led recent follow-ons with a $569.2m offering.
- Drug Delivery
- Antisense, Oligonucleotides
- Large Molecule
- Synthesis Technologies, Production Processes
- Other Names / Subsidiaries
- Regulus Therapeutics, Inc.
- Sirna Therapeutics, Inc. Alnylam U.S., Inc Ribopharma AG